mRNA-6231 / Moderna - LARVOL DELTA

Translational kinetic-pharmacodynamics of mRNA-6231, an investigational mRNA therapeutic encoding mutein interleukin-2. (PubMed, CPT Pharmacometrics Syst Pharmacol) - P1 | "The modeling approach used to predict human responses was validated when data became available from the phase I clinical study. This validation indicates that the approach is valuable in informing clinical decision-making."

Journal • PK/PD data • Immunology • IL2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults (clinicaltrials.gov) - P1 | N=18 | Completed | Sponsor: ModernaTX, Inc. | Recruiting ➔ Completed | N=52 ➔ 18 | Trial completion date: Feb 2023 ➔ Aug 2022 | Trial primary completion date: Dec 2022 ➔ Aug 2022

Enrollment change • Trial completion • Trial completion date • Trial primary completion date

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults (clinicaltrials.gov) - P1 | N=52 | Recruiting | Sponsor: ModernaTX, Inc. | N=112 ➔ 52 | Trial completion date: Nov 2022 ➔ Feb 2023 | Trial primary completion date: Sep 2022 ➔ Dec 2022

Enrollment change • Trial completion date • Trial primary completion date

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults (clinicaltrials.gov) - P1; N=112; Recruiting; Sponsor: ModernaTX, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open